4LSC2845 [D7]-Bortezomib

Bortezomib is an anti-cancer drug and the first therapeutic proteasome inhibitor to be used in humans. Stable isotope labeled Bortezomib is intended for use as an internal standard for the quantification of Bortezomib by LC or GC-mass spectrometry.

If the number, nature and/or location of stable isotope label atoms (D, ¹⁵N, ¹³C) in this molecule don’t fit with your application, don’t hesitate to contact us to discuss your specific needs.

Keywords:

Stable isotope labeled active pharmaceutical ingredient (API), stable isotope dilution analysis, internal standard, stable isotope labeled standard (SIL), therapeutic drug monitoring (TDM), quantitative bioanalytical method validation, clinical diagnosis, LC/MS method validation, quantitative proteomics, selective reaction monitoring (SRM), multiple reaction monitoring (MRM), peptide based quantitative proteomics, custom stable isotope labeled (SIL) peptide, diagnostic breath test, clinical chemistry, diagnostic tools & biomarkers.

• Molecular Formula: C₁₉H₁₈D₇BN₄O₄
• Molecular Weight: 391.29 g/mol
• Specification:
  Minimum chemical purity: 95.0 %
  Minimum Isotopic Enrichment: ²H ≥98 %
• Solubility: Methanol (MeOH), Dimethylsulfoxide (DMSO),
• HS Code: 284590

N/A